Bruce E. Johnson, MD

Two different clinical trials using biological agents directed against an autocrine growth factor and a surface marker of neuroendocrine differentiation have been used for patients with relapsed small-cell lung cancer. In a

The treatment of potentially curable non-small-cell lung cancer (NSCLC) is currently evolving. Drs. Greco and Hainsworth provide information about the potential use of chemotherapy, radiation, and surgery in patients with stage IB-IV NSCLC. The authors have taken on the challenging task of summarizing recent clinical research, referencing current clinical studies, and providing some predictions on the outcomes of ongoing clinical investigation.

Dr. Vokes provides information about integrating a new chemotherapeutic agent, vinorelbine (Navelbine), into the current treatment regimens for patients with advanced-stage non-small-cell lung cancer. He reviews the phase II activity of